Nearly nine years ago, when Emma Walmsley was preparing to take over as CEO of GSK Plc, she wrote in her diary that Luke Miels — then an executive at rival AstraZeneca Plc — would be “a dream appointment for this adventure.”
Walmsley’s Dream Hire Badly Needs to Find Some Blockbuster Drugs